药学学报, 2021, 56(11): 2995-3003
引用本文:
龚普阳, 尹可欢, 李雪冬, 顾健, 谭睿. 藏药防治肝纤维化的临床与药理研究进展[J]. 药学学报, 2021, 56(11): 2995-3003.
GONG Pu-yang, YIN Ke-huan, LI Xue-dong, GU Jian, TAN Rui. Clinical and pharmacological research progress of Tibetan medicine in prevention and treatment for hepatic fibrosis[J]. Acta Pharmaceutica Sinica, 2021, 56(11): 2995-3003.

藏药防治肝纤维化的临床与药理研究进展
龚普阳1, 尹可欢1, 李雪冬1, 顾健1*, 谭睿2
1. 西南民族大学药学院, 四川 成都 610041;
2. 西南交通大学生命科学与工程学院, 四川 成都 610031
摘要:
肝纤维化是多种慢性肝脏疾病的共有病理环节,并最终导致肝硬化甚至肝癌的发生。藏医药防治肝纤维化独具优势,其通过单一复方、时辰协同及辩证组合等特色用药方式发挥显著临床疗效。现代药理研究表明,多种藏药方剂及药材可通过抑制脂质过氧化、减少肝星状细胞活化与增殖和胶原代谢调节等方式发挥抗肝纤维化作用。通过归纳总结现有文献,从藏医病因病机、临床用药及药效机制等方面对藏药防治肝纤维化现代研究进展进行综述,以期为其临床合理应用与创新药物开发提供参考。
关键词:    藏药      肝纤维化      临床应用      药效机制      新药开发     
Clinical and pharmacological research progress of Tibetan medicine in prevention and treatment for hepatic fibrosis
GONG Pu-yang1, YIN Ke-huan1, LI Xue-dong1, GU Jian1*, TAN Rui2
1. College of Pharmacy, Southwest Minzu University, Chengdu 610041, China;
2. College of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China
Abstract:
Hepatic fibrosis is a common pathological link of multiple chronic liver diseases, and further causes cirrhosis and even liver cancer. Tibetan medicine possessed significant and unique clinical effects in the prevention and treatment of hepatic fibrosis through unique medication methods such as single prescription, time synergy, and dialectical combination prescription. Pharmacological experimental studies have shown that a variety of Tibetan medicine formulas and herbs have anti-fibrotic effects, and their main pharmacological action mechanism involves inhibiting lipid peroxidation, reducing liver stellate cell activation and proliferation, regulating collagen metabolism, etc. This review summarizes the research progress of the clinical application and pharmacodynamic mechanism of Tibetan medicine in the prevention and treatment of liver fibrosis, aiming to provide a reference for the development of clinical use and innovative drugs discovery of Tibetan medicine against hepatic fibrosis.
Key words:    Tibetan medicine    hepatic fibrosis    clinical application    pharmacological mechanism    drug development   
收稿日期: 2021-02-23
DOI: 10.16438/j.0513-4870.2021-0264
基金项目: 国家自然科学基金资助项目(82004069);四川省重点研发计划项目(20ZDYF3291);西南民族大学中央高校基本科研业务费专项资金项目(2020NYBPY14).
通讯作者: 顾健,Tel:86-28-85656463,E-mail:gujiancd@163.com
Email: gujiancd@163.com
相关功能
PDF(1094KB) Free
打印本文
0
作者相关文章
龚普阳  在本刊中的所有文章
尹可欢  在本刊中的所有文章
李雪冬  在本刊中的所有文章
顾健  在本刊中的所有文章
谭睿  在本刊中的所有文章

参考文献:
[1] Shan L, Liu Z, Ci L, et al. Research progress on the anti-hepatic fibrosis action and mechanism of natural products[J]. Int Immunopharmacol, 2019, 75: 105765
[2] Wang X, Fu T, Wang J, et al. Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation[J]. Int Immunopharmacol, 2019, 75: 105833.
[3] Friedman SL. Hepatic fibrosis—overview[J]. Toxicology, 2008, 254: 120-129.
[4] Xia HS, Chen SR, Zhong YC, et al. Pathogenesis of liver fibrosis and its treatment status[J]. Chin Med Herald (中国医药导报), 2014, 11: 162-168.
[5] Peng MDZ, La MZM. Study on the understanding and treatment of cirrhosis in Tibetan medicine[J]. J Med Pharm Chin Minor (中国民族医药杂志), 2016, 6: 53-55.
[6] Xizhu JC. A brief discussion on understanding of Tibetan medicine on liver and liver diseases[J]. China Tibetol (中国藏学), 2010, 4: 155-158.
[7] Ciren BZ, Gu J, Shi ZL. To explore the core composition and compatibility features of Tibetan medicine Ershiwuwei Songshi Pills in the treatment of liver disease[J]. World Sci Technol Mod Tradit Chin Med (世界科学技术-中医药现代化), 2018, 20: 140-145.
[8] Gengzang DZ, Kamao CR. The clinical application of Tibetan medicine Shiliu Rilunkacisan against liver fibrosis[J]. J Med Pharm Chin Minor (中国民族医药杂志), 2017, 7: 27.
[9] Feng X. Study on Anti-hepatic Fibrosis Effect and Mechanism of Tibetan Medicine (藏药波棱瓜子抗肝纤维化作用及机理研究)[D]. Beijing: Beijing University of Chinese Medicine, 2018.
[10] Lan KJ, Que Z. Treatment plan of Tibetan medicine for liver cirrhosis[J]. J Med Pharm Chin Minor (中国民族医药杂志), 2011, 17: 63.
[11] Deqing BZ, Bai M, Bai Y, et al. Clinical observation on therapeutic effect of liver cirrhosis (Mchim Khray Smug porgyas pa) treated with Tibetan medicine[J]. World Sci Technol Mod Tradit Chin Med (世界科学技术-中医药现代化), 2013, 15: 1009-1014.
[12] De J, Bai M. Clinical observation of Tibetan medicine Dangmatruzhen in the treatment of ascites due to liver cirrhosis[J]. Chin J Integr Tradit West Med Liver Dis (中西医结合肝病杂志), 2019, 29: 33-34.
[13] Pengmao CD, Tai B. Study on the clinical curative effect of Tibetan medicine Shisanwei Honghua Pills against liver fibrosis[J]. J Med Pharm Chin Minor (中国民族医药杂志), 2013, 6: 23.
[14] Zhuo M, Lan KJ. Clinical analysis on the treatment of 36 cases of liver cirrhosis with Tibetan medicine Shibawei Daxiang Honghua Powder[J]. J Med Pharm Chin Minor (中国民族医药杂志), 2007, 3: 21.
[15] Zhang JW, Gao JJ, Liu DL, et al. Clinical study on Ershiwuwei Songshi Pills combined with entecavir in treatment of chronic hepatitis B[J]. Drug Clin (现代药物与临床), 2019, 34: 212-216.
[16] Wanma LD. A clinical research on Tibetan medicine saffron pill composed of eighteen medicinals's anti-fibrosis effect on liver[J]. Clin J Chin Med (中医临床研究), 2014, 6: 94-95.
[17] Ji B, Zhuoma T. Clinical observation on Tibetan medicine treating 50 cases of early liver cirrhosis[J]. J Med Pharm Chin Minor (中国民族医药杂志), 2009, 8: 12.
[18] Dangzeng CR, Niangmao ZX. Observation on curative effect of oral Tibetan medicine and external treatment of Tibetan medicine in treating liver cirrhosis[J]. J Med Pharm Chin Minor (中国民族医药杂志), 2020, 26: 27-28.
[19] Shi XT, OuYang XH, Su XL. Research progress of anti-hepatic fibrosis drug treatment[J]. Med Recapit (医学综述), 2019, 25: 480-489.
[20] Gao YP, Wang NP. Effect of Tibetan medicine Songshi pill on experimental liver fibrosis rats[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2005, 11: 47-48.
[21] Peng YR, Ding YF, Luo YH, et al. Experimental study on the therapeutical effect of Lang Qing A Ta on hepatic fibrosis[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2012, 18: 190-194.
[22] Jing XY, Ding YF, Huang YP, et al. Effect of LangQing Ata on TGF-β, α-SMA and OB-R of collagen in rat hepatic fibrosis model[J]. Mod Chin Med (中国现代中药), 2015, 17: 1258-1262.
[23] Xue J, Peng YR, Ding YF, et al. Effect of Langqing Ata on metabolism of collage in rat hepatic fibrosis model[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2012, 18: 260-265.
[24] Chen WW, Wang HR, Huo X, et al. Therapeutic effect of Renqing Mangjue capsule on liver fibrosis rats induced by DMN[J]. Drug Eval Res (药物评价研究), 2019, 42: 1099-1104.
[25] Huang LL. The Protective Effect and Mechanism of ZYJN on Experimental Liver Injury (藏药苦空确屯卡察尔保肝作用研究及机制探讨)[D]. Chengdu: Chengdu University of Traditional Chinese Medicine, 2009.
[26] Feng HL, Wang NP. Effect of Qishiwei Songshi Pill on experimental cirrhosis in rats[J]. Chin Tradit Pat Med (中成药), 2005, 27: 741-742.
[27] Liu W, Fu XH, Huang SY, et al. Protective effect and mechanism of total lignans from Tibetan medicinal Herpetospermum seeds on carbon tetrachloride induced liver fibrosis in rats[J]. China J Chin Mater Med (中国中药杂志), 2017, 42: 567-571.
[28] Liu W, Shi LL, Shi YC, et al. Effects of total lignans from Tibetan medicine Herpetospermum pedunculosum seeds on proliferation and apoptosis of rat hepatic stellate cells[J]. Chin Tradit Herbal Drugs (中草药), 2017, 48: 2912-2917.
[29] Wang ZW, Wang RQ, Guo M, et al. Influence of active fractions of Meconopsis quintuplinervia Regel growing in Gansu province on antioxidant system of experimental liver fibrosis rat[J]. Chin J Gerontol (中国老年学杂志), 2013, 33: 5043-5046.
[30] Wang ZW, Shao J, Guo M, et al. Effect of total flavonoids and alkaloids from Meconopsis quintuplinervia on hepatic fibrosis in rat[J]. Chin Tradit Pat Med (中成药), 2013, 35: 1125-1128.
[31] Wang ZW, Cheng XL, Guo M, et al. Influence of active fractions of MQR growing in Gansu province on effect and expression of TGF-β1 of experimental liver fibrosis in rat[J]. Chin J Immunol (中国免疫学杂志), 2013, 29: 135-139.
[32] Wang ZW, Shao J, Guo M. Influence of the active fractions of Meconopsis quintuplinervia Regel growing in Gansu region on inflammatory cytokines in experimental liver fibrosis rat[J]. Immunol J (免疫学杂志), 2013, 29: 24-27.
[33] Wang Q, Zhong LH, Yu L, et al. Effects of Zanghonghua on expression of transforming growth factors-β1 in rats with liver fibrosis[J]. Prog Mod Biomed (现代生物医学进展), 2012, 12: 3228-3231, 3262.
[34] Wang Y, Zhu LY. Experimental study on the treatment of rat hepatic fibrosis with saffron[J]. Prog Mod Biomed (现代生物医学进展), 2010, 10: 3244-3247.
[35] Yang PQ, Wang Y, Mei XQ, et al. Effects of crocetin on signal transduction pathway of human hepatic stellate cells stimulated by TGF-β1[J]. Prog Mod Biomed (现代生物医学进展), 2018, 18: 3230-3234.
[36] Mei XQ, Wang Y, Wang FX, et al. The influence of saffron in expression of apoptosis related protein caspase-3, Bcl-2 in rats with liver fibrosis[J]. Prog Mod Biomed (现代生物医学进展), 2016, 16: 4427-4430.
[37] Wang FX, Wang Y, Mei XQ, et al. An experimental study on the treatment of liver fibrosis with crocetin[J]. Prog Mod Biomed (现代生物医学进展), 2017, 17: 5432-5435, 5577.
[38] He DD, Xu MD, Zeng BL, et al. Effects of Swertia chirayita on hepatic fibrosis model rats induced by carbon tetrachloride[J]. Chin J Tradit Chin Med Pharm (中华中医药杂志), 2017, 32: 4680-4683.
[39] Chen XQ. Study on Anti-hepatic Fibrosis Component from Ethylacetate Fraction of Swertia chirayita (印度獐牙菜乙酸乙酯部位抗肝纤维化活性成分研究)[D]. Hefei: Anhui University of Chinese Medicine, 2018.
[40] Wei SL, Wang J, Li DM. Inhibitory effect of Swertiamarin on fibrosis in rats with cholestatic liver damage[J]. World Chin J Digestol, 2016, 24: 3482-3487.
[41] Yang H, Zhang Y, Tan WC, et al. Anti-fibrosis effects of "Duyiwei Granule" on hepatic fibrosis[J]. Shanghai J Tradit Chin Med (上海中医药杂志), 2010, 44: 64-67.
[42] Jiang H, Li KQ, Li X, et al. Protective effects of effective components group of medicine Terminalia Fruit on experimental liver fibrosis[J]. J Int Pharm Res (国际药学研究杂志), 2013, 40: 611-614.
[43] Min H, Hu CH, Hu B, et al. Optimization of extraction technology of total alkaloids from Sophora Moorcroftiana based on multi index comprehensive detection and its mechanism of anti-hepatic fibrosis[J]. Guid J Tradit Chin Med Pharm (中医药导报), 2018, 24: 14-18.
[44] Han Q, Wei LX, Du YZ. Experimental study on the effect of glycosides in Swertiam mussotii against carbon tetrachloride-induced liver fibrosis in rats[J]. Chin Tradit Pat Med (中成药), 2009, 31: 936-937.
[45] Li P, Yang ZT, Peng BC, et al. Effect of Phyllanthus emblica L. on immunity hepatic fibrosis in rats[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2010, 16: 171-173.
[46] Feng JL, Shen HR, Li X, et al. Effect of Fangji Huangqi Decoction on liver mitochondrial per-oxidative injury in hepatic fibrosis mice induced by lipopolysaccharide and nitrosodimethylamine[J]. Tradit Chin Drug Res Clin Pharmacol (中药新药与临床药理), 2010, 21: 506-508.
[47] Fei Y, Zhang QY, Jiao L, et al. Synergistic hepatoprotective effect of Schisandrae lignans with Astragalus polysaccharides on chronic liver injury in rats[J]. Phytomedicine, 2009, 16: 805-813.
[48] Lin Y, Luo H, Wang X, et al. Flavanones from Sedum sarmentosum bunge alleviate CCl4-induced liver fibrosis in rats by targeting TGF-β1/TβR/Smad pathway in turn inhibiting epithelial mesenchymal transition[J]. Evid Based Complement Alternat Med, 2018, 8: 3080837.
[49] Katsunori Y, Miki M, Takashi Y, et al. TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review)[J]. Int J Oncol, 2014, 45: 1363-1371.
[50] Fabregat I, Moreno-Càceres J, Sánchez A, et al. TGF-β signaling and liver disease[J]. FEBS J, 2016, 283: 2219-2232
[51] Hashemi M, Hosseinzadeh H. A comprehensive review on biological activities and toxicology of crocetin[J]. Food Chem Toxicol, 2019, 130: 44-60.
[52] Koscianska E, Baev V, Skreka K, et al. Prediction and preliminary validation of oncogene regulation by miRNAs[J]. BMC Mol Biol, 2007, 8: 79-87.
[53] Zheng J, Wu C, Xu Z, et al. Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway[J]. Mol Cell Biochem, 2015, 398: 1-9.
[54] Wei Z, Zhao D, Zhang Y, et al. Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-κB-TNF-α signaling pathway in a PPARγ-dependent manner[J]. Biochem Biophys Res Commun, 2019, 519: 854-860.
[55] Kubo N, Saito R, Hamano K, et al. Conophylline suppresses hepatic stellate cells and attenuates thioacetamide-induced liver fibrosis in rats[J]. Liver Int, 2014, 34: 1057-1067.
[56] Zhang N, Li LS. Research progress on pharmacological effects of Crocus sativus and its active ingredients[J]. Drug Eval Res (药物评价研究), 2013, 36: 394-396.
[57] Zhang YH, Liu JT. Progress in mechanism of traditional Chinese herbs against hepatic fibrosis[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2006, 12: 66-70.
[58] Caviglia GP, Ciancio A, Rosso C, et al. Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment[J]. Ann Hepatol, 2013, 13: 91-97.
[59] Jing J, Zhao JY, Hua B, et al. Inhibitory effect of flavonoids from Glycyrrhiza uralensis on expressions of TGF-β1 and caspase-3 in thioacetamide-induced hepatic fibrosis in rats[J]. China J Chin Mater Med (中国中药杂志), 2015, 40: 3034-3040.
[60] Zhang Y, Zhou Q, Ding X, et al. Chemical profile of Swertia mussotii Franch and its potential targets against liver fibrosis revealed by cross-platform metabolomics[J]. J Ethnopharmacol, 2021, 274: 114051.
[61] Tian CW, Zhang TJ. Determination of Swertiopicrin and gentiopicrin in Swertiam mussotii by HPLC[J]. Chin Tradit Herbal Drugs (中草药), 2006, 37: 442-443.
[62] Shi M, Xiong K, Zhang T, et al. Pharmacokinetics and metabolic profiles of swertiamarin in rats by liquid chromatography combined with electrospray ionization tandem mass spectrometry[J]. J Pharm Biomed Anal, 2020, 179: 112997.
[63] Hairul-Islam MI, Saravanan S, Thirugnanasambantham K, et al. Swertiamarin, a natural steroid, prevent bone erosion by modulating RANKL/RANK/OPG signaling[J]. Int Immunopharmacol, 2017, 53: 114-124.